Document:

Exhibit 4.11.7

    

    

      	
              AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

            	 	
              1. CONTRACT ID CODE

            	 	
              PAGE OF PAGES

            
	 	 	 	 	
              1

            	
              5

              

            
	
              2. AMENDMENT/MODIFICATION NO.

            	
              3. EFFECTIVE DATE

            	
              4. REQUISITION/PURCHASE REQ. NO.

            	
              5. PROJECT NO. (If applicable)

            
	
              P00008

            	 	
              See Block 16C

            	
              OS289937

            	 	 	 	 
	
              6. ISSUED BY

            	
              CODE   

            	
              ASPR-BARDA

            	
              7. ADMINISTERED BY (If other than Item 6)

            	
              CODE

            	
              ASPR-BARDA01

            
	 	 	 	 	 	 
	
              ASPR-BARDA

            	
              ASPR-BARDA

            	 	 	 	 
	
              200 Independence Ave., S.W.

            	
              330 Independence Ave, SW, Rm G644

            
	
              Room 640-G

            	
              Washington DC 20201

            
	
              Washington DC 20201

            	 	 	 	 	 
	 	 	 	 	 	 
	
              8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

            	
              (x)

            	
              9A. AMENDMENT OF SOLICITATION NO.

            
	 	 	 	 	 	 	 	 	 	 
	
              MEDIWOUND LTD 1477616

            	 	 	 	 	 	 	 	 	 
	
              MEDIWOUND LTD

            	
              42 HAYARKON

            	 	 	
              9B. DATED (SEE ITEM 11)

            
	
              42 HAYARKON

            	 	 	 	 	 	 	 	 	 
	
              YAVNE     00812

            	 	 	
              x

            	
              10A. MODIFICATION OF CONTRACT/ORDER NO.

            
	 	 	 	 	
              HHSO100201500035C

            	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	
              10B. DATED (SEE ITEM 13)

            	 	 	 	 
	
              CODE      1477616

               

            	 	
               FACILITY CODE

               

            	 	
              09/29/2015

               

            	 	 	 	 
	
              11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

            

      	
              ☐

            	
              The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers      ☐ is extended.   ☐ is not extended.

            
	 	
              Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning ________ copies of the amendment;
                (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED
                AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by
                telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

            

      	
              12. ACCOUNTING AND APPROPRIATION DATA (If required)

            	
              Net Increase:

            	
              
                $8,944,500.00

              

            
	
              
                See Schedule

              

            	 	 
	
              13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

               

            
	
              CHECK ONE

            	
              A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

               

            
	 
	 	
              B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.)
                SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

               

            
	
              X

            	
              C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

              
                
                  FAR 52.243-2 Alt I - Changes - Cost Reimbursement and FAR 43.103(a) - By Mutual Agreements of the Parties

                

              

            
	 	
              D. OTHER (Specify type of modification and authority)

               

            
	
              E. IMPORTANT: Contractor ☐ is not.  ☒ is required to sign this document and return      1      copies to the issuing office.

            

       14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

       

        

       
      
        	
                Tax ID Number:

              	
                C0-0000387

              
	DUNS Number:	532040334

        
          The purpose of this modification is to add funds to CLIN 0001 for increased costs as a result of FDA comments, and modify ARTICLE B.2. BASE PERIOD,
            ARTICLE C.1. STATEMENT OF WORK, ARTICLE G.1. CONTRACTING OFFICER, ARTICLE G.5. INDIRECT COST RATES, and SECTION J.

           

          Funds Obligated Prior to this Modification: $ 98,418,394 

          Funds Obligated with Mod # 8: $ 8,944,500

          Total Funds Obligated to Date: $ 107,362,894

          

          

          Continued ...

        

          

        

      

      Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.

      	
              15A. NAME AND TITLE OF SIGNER (Type or print)

            	
               16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

            
	 	 
	
              Sharon Malka, CEO

            	
              
                KEVIN RESTREPO

              

            	 
	
              15B. CONTRACTOR/OFFEROR

            	
              
                15C. DATE SIGNED+

              

            	
               16B. UNITED STATES OF AMERICA

            	
              16C. DATE SIGNED

            
	
                           /s/ Sharon Malka                      

                

            	
              
                02/08/2022

              

            	
              
                           /s/ KEVIN RESTREPO         

              

            	
              
                

                

              

            
	
              (Signature of person authorized to sign)

            	 	
              (Signature of Contracting Officer)

            	
              
                02/09/2022

              

            

      	
              
                Previous edition unusable

              

            	
              
                STANDARD FORM 30 (REV. 11/2016)

              

            
	
              

              

            	
              
                Prescribed by GSA FAR (48 CFR) 53.243 

              

            
	 	

            

       

      
        
          
            

        

        	 	 	 	 
	
                CONTINUATION SHEET

              	
                REFERENCE NO. OF DOCUMENT BEING CONTINUED

              	
                PAGE OF

              
	
                
                  HHSO100201500035C/P00008

                

              	
                2

              	
                5

                

              

        NAME OF OFFEROR OR CONTRACTOR

        MEDIWOUND LTD 1477616

        	
                ITEM NO.

                (A)

              	
                SUPPLIES/SERVICES

                (B)

              	
                QUANTITY

                (C)

              	
                UNIT

                (D)

              	
                UNIT PRICE

                (E)

              	
                AMOUNT

                (F)

              
	 	
                
                  
                    In consideration of the modification agreed to herein as complete equitable adjustments, the Contractor, hereby releases the Government from any and all liability under this contract for further equitable
                      adjustments attributable to such fact or circumstance giving rise to this modification.

                  

                

              	 	 	 	 
	 	
                
                  
                    

                    

                  

                

              	 	 	 	 
	 	
                
                  
                    Period of Performance: 09/29/2015 to 09/27/2024

                  

                

              	 	 	 	 
	 	
                
                  

                  

                

              	 	 	 	 
	 	
                
                  Change Item 1 to read as follows(amount shown is the obligated amount):

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	1

              	
                
                  ASPR-15-08828 -- CLIN 0001          Advanced development studies for NexoBrid
                    

                  

                

              	 	 	 	
                8,944,500.00

              
	 	
                

                

              	 	 	 	 
	 	
                Accounting Info:

                2015.1990002.26201 Appr. Yr.: 2015 CAN: 1990002   Object Class:   26201

                Funded: $0.00

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                
                  
                    Accounting Info:

                    2017.1990007.25106 Appr. Yr.: 2017 CAN: 1990007  Object Class:    25106

                    Funded: $0.00

                  

                

              	 	 	 	 
	 	 	 	 	 	 
	 	
                Accounting Info:

                2019.1990051.25106 Appr. Yr.: 2019 CAN: 1990051 Object Class:    25106

                Funded: $0.00

              	 	 	 	

              
	 	 	 	 	 	 
	

              	
                Accounting Info:

                2022.1990178.25103 Appr. Yr.: 2022 CAN: 1990178 Object Class:   25103 

                Funded: $8,944,500.00

              	 	 	 	

              
	 	
                
                  

                  

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	
                

                

              	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

        	
                NSN 7540-01-152-8067

              	
                OPTIONAL FORM 336 (4-86)

              
	 	
                Sponsored by GSA

              
	 	
                FAR (48 CFR) 53.110

              

      

       

      

    

    
      
        

    

     

    

    	
            Contract No. HHSO100201500035C

            
              Modification # 8

            

          	
            Supplemental Pages Block 14

          	
            Page 3 / 5

            

          

    

    

    
      SUMMARY OF CHANGES

       

      Beginning with the effective date of this modification, the Government and Contractor mutually agree as follows:

       

      	1.	
              ARTICLE B.2. BASE PERIOD, is modified to add funding to CLIN 0001.

            

      	2.	
              ARTICLE C.1. STATEMENT OF WORK, is modified to delete reference to the date of the Statement of Work.

            

      	3.	
              ARTICLE G.1. CONTRACTING OFFICER, is modified to replace Matthew Rose with Jill Johnson.

            

      	4.	
              ARTICLE G.5. INDIRECT COST RATES, is modified to reflect current mutual understanding of indirect rates.

            

      	5.	
              SECTION J, Attachment 1, SOW, is replaced in its entirety.

            

    

    

    

    
      ARTICLE B.2. BASE PERIOD is modified as follows:

    

    

    

    
      	
              CLIN

            	
              Period of Performance

            	
              Supplies/ Services

            	
              Total Est.

              Cost

            	
              Fixed Fee (7%)

            	
              Total Cost Plus Fixed 

              Fee

            
	
               COST REIMBURSEMENT

            
	
              0001

              (Base)

            	
              09/28/2015 –

              09/27/2024

            	
              Licensure, approval, and clearance

              of product through the FDA

            	
              $47,911,779

              $55,986,743

            	
              $3,049,644

              $3,919,180

            	
              $50,961,423

              $59,905,923

               

              (Funded)

            
	
              0004A

              (Base)- Activate optional Task in July, 2017

            	
              08/01/2017-

              07/31/2023

            	
              Pediatric Study

            	
              $23,989,225

            	
              $1,455,400

            	
              $25,444,625

               

              (Funded)

            
	
              0006A,B,C

              (Base) New Task added in Feb 28,2020

            	
              1/1/2020 -

              6/31/2024

            	
              Emergency Readiness Tasks

            	
              $4,271,919

            	
              $299,034

            	
              $4,570,953

               

              (Funded)

            
	
              0007A,B

              (Base) New Task added in Feb 28,2020

            	
              TBD

            	
              Emergency Deployment Preparation

            	
              $903,350

            	
              $63,235

            	
              $966,585

              (Funded)

            
	
               FIRM FIXED PRICE

            
	
              CLIN

            	
              Period of Performance

            	
              Supplies/ Services

            	
              Units (# of Product)

            	
              Unit Price ($)

            	
              Total ($)

            
	
              0002

              (Base)

               

            	
              09/28/2017 –

              09/27/2019*(*

              see advanced 

                understanding h.)

              

            	
              Initial Purchase, storage, and

              delivery of product

               

            	
              10,588

            	
              $1,052

              (includes

              VMI)

            	
              $11,138,576

              (Funded)

               

            

    

    
      	
              0002

              (Base)

            	
              09/28/2019 –

              3/31/2022

            	
              Initial Purchase, storage, and

              delivery of product

            	
              5412

            	
              $986

              (includes

              VMI)

            	
              $5,336,232

              (Funded)

            
	
              Total

              CLINS

              001&002&0

              04A&006&0

              07

            	
              09/28/2015 –

              09/27/2024

            	
              See Above Descriptions

            	 	 	
              $98,418,395 

              107,362,894

              (Funded)

            

    

    

    

     

    
      
        

    

     

    

    

    	
            Contract No. HHSO100201500035C

            
              Modification # 8

            

          	
            Continuation Sheet 

            Block 14

          	
            Page 4 / 5

            

          

     

    
      ARTICLE C.1. STATEMENT OF WORK  is modified as follows:

       

      Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities not
        otherwise provided by the Government as needed to perform the Statement of Work dated September 28, 2015 set forth in SECTION J - List of Attachments, attached hereto and made a part of the contract.

       

      ARTICLE G.1. CONTRACTING OFFICER is modified as follows:

       

      The following Contracting Officer (CO) will represent the Government for the purpose of this contract:

       

      
        Jill Johnson, Contracting Officer

        
          202-690-7137

          
            Jill.Johnson@hhs.gov

          

        

      

       

      

      	a.	
              The Contracting Officer (CO) is the only individual who can legally commit the Government to the expenditure of public funds. No person other than the CO can make any changes to the terms, conditions, general provisions, specifications
                or other requirements of this contract.

            

       

      	b.	
              The Contracting Officer (CO) is the only person with authority to act as agent of the Government under this contract. Only the CO has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the
                period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs incurred during the performance of this contract; or (5) otherwise change any terms and conditions of this contract.

            

       

      	c.	
              No information, other than that which may be contained in an authorized modification to this contract duly issued by the CO, shall be considered grounds for deviation from this contract.

            

       

      	d.	
              The Government may unilaterally change its CO designation

            

    

    

    
      
        

    

      

    	
            Contract No. HHSO100201500035C

            Modification # 8

          	
            Continuation Sheet 

            Block 14

          	
            Page 5 / 5

            

          

       

    
      ARTICLE G.5. INDIRECT COST RATES is modified as follows:

       

      	1.	
              The following interim provisional indirect rates will be utilized for billing purposes during the period of performance:

            

      

      

      Direct Labor Overhead - 80%.

      Direct Consultant Labor Overhead – 25%

      Final rate proposals must be sent to the Contracting Officer, within 6 months of the fiscal year end. See FAR Clause 52.216-7, Allowable Cost and Payment.

       

      	2.	
              The interim provisional indirect rates used in this contract have been established after approval by the AMCG/BARDA Auditor.

            

      

      

      SECTION J LIST OF ATTACHMENTS is modified as follows:

       

      The following documents are attached and incorporated in this contract:

       

      	

            	1.	
              Statement of Work, dated January 26, 2022

            

       

      	

            	2.	
              Invoice/Financing Instructions for Cost-Reimbursement Type Contracts

            

       

      	

            	3.	
              Invoice Instructions for Fixed-Priced Type Contracts

            

       

      	

            	4.	
              Sample Invoice Form

            

       

      	

            	5.	
              Research Patient Care Costs

            

       

      	

            	6.	
              Report of Government Owned, Contractor Held Property

            

       

      	

            	7.	
              Form SF-LLL, Disclosure of Lobbying Activities

            

       

      	

            	8.	
              Inclusion Enrollment Report, 5/01 (Modified OAMP: 10/01)

            

      

      

      END OF MODIFICATION P00008 to HHSO100201500035CDocument

        Exhibit 10.40
[****] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.  

cope
Part A: Project Overview
Executive Summary of the Opportunity

Patheon, part of Thermo Fisher Scientific has been contracted by Zosano to produce Zolmitriptan microneedle patches.

The project work will occur at Patheon’s [****] facility. All services and/ or work to be performed pursuant to this proposal shall be performed or supplied subject to the terms and conditions set forth in the Manufacturing and Supply Agreement by and between Zosano Pharma Corporation (“Client”) and Patheon Manufacturing Services, LLC (“Patheon”), effective September 25, 2018 and such terms and conditions shall specifically be incorporated in and be applicable to this proposal unless otherwise agreed by the Parties in writing.

This proposal captures modification of [****] base fees as directed in Schedule B of the MSA. This proposal is specific to [****] fees only.

This Change of Scope is supplemental to the Existing Agreement. Except as expressly amended by this Change of Scope, the Existing Agreement shall remain in full force and effect. Terms defined in the Existing Agreement shall have the same meaning in this Change of Scope, unless otherwise provided by this Change of Scope.
			
	

			
	

[****] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Part B: Pricing

																					
		Year	

Base Fee
	

Payment Structure
	Covered Volume/Base Fees and Product Fees
	

First Payment Due
	

End Date

						

	
	

Current Fees
	

[****]
	

[****]
	12 Equal Monthly Payments
	

[****]
	

[****]
	

[****]

						

	
						

	
	

Proposed Fees
	

[****]
	

[****]
	12 Equal Monthly Payments
	

[****]
	

[****]
	

[****]

						

	
	*Revised base fee is subject to terms and conditions in Part C and D. Any increase in volumes or assumptions would result in modification of fees.

Part C: Technical Assumptions
•Proposed [****] base fee assumes a 16/5 shift structure. A 16/5 shift structure is the minimum labor requirement and cannot be further reduced. Any increase in volume beyond [****] would result in the need for a labor analysis to be conducted by Patheon and potential need for 24/7 shift structure resulting in an increase of base fees.

•[****] assumes [****] financial liability for batches impacted due to unforeseen circumstances resulting from the lack of a 24/7 shift structure.

•[****] and beyond requires the utilization of a 24/7 shift structure

[****] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Part D: General Assumptions, Terms and Conditions
The following additional Terms and Conditions are applicable:

•All stated Values/Invoices are in ($) US Dollars.

•Payment Schedule:
o Activities will be invoiced upon completion.

•This proposal is valid for 60 days.

•Should any of the assumptions contained in this Change of Scope prove to be inaccurate, Patheon reserves the right to adjust the Budget Summary accordingly.

												
	 Patheon
	Zosano Pharma Corporation

	5900 Martin Luther King Jr Hwy Greenville, NC 27834
USA
	34790 Ardentech Court
Fremont, CA 94555 USA

	By:
	/s/ Alicia Walter
	By:
	/s/ Steven Lo

	Name:  Alicia Walter
	Name:   Steven Lo    

	

Title:    Senior Business Manager
	

Title:
	

 President & Chief Executive Officer    

	

Date:
	

November 19, 2021
	

Date:
	

 December 1, 2021    

	
	

Finance contact:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]